Mark J Stanley

US Patent:

6667318, Dec 23, 2003

Filed:

Nov 26, 2001

Appl. No.:

09/994546

Inventors:

Daniel J. Burdick - Burlingame CA
Mark S. Stanley - Pacifica CA
David Oare - Belmont CA
Mark E. Reynolds - Millbrae CA
Thomas R. Gadek - Oakland CA
James C. Marsters - Oakland CA

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K 314525

US Classification:

514326, 546214, 548182, 548200, 548517, 549473, 514365, 514369, 514422

Abstract:

The invention relates to novel compounds having formula (I) wherein Cy, X, Y, L and R are as defined herein. The compounds bind CD11/CD18 adhesion receptors such as Lymphocyte Function-associated Antigen-1 (LFA-1) and are therefore useful for treating disorders mediated by LFA-1 such as inflammation and autoimmune diseases.

US Patent:

6706753, Mar 16, 2004

Filed:

Dec 6, 2002

Appl. No.:

10/313147

Inventors:

Dean R. Artis - Kensington CA
David Y. Jackson - San Bruno CA
Thomas E. Rawson - Mountain View CA
Mark E. Reynolds - Millbrae CA
Daniel P. Sutherlin - South San Francisco CA
Mark S. Stanley - Pacifica CA

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K 314025

US Classification:

514422, 548517, 548537, 548538, 514423

Abstract:

Provided are compounds of formula (I) wherein A, Q, W, X, Y, Z, R to R , m and n are as defined herein. Compounds of the invention bind to integrin receptors and thereby inhibit binding of ligands for integrins which is useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with integrins or their ligands.

US Patent:

6872735, Mar 29, 2005

Filed:

Jul 11, 2003

Appl. No.:

10/618178

Inventors:

Daniel J. Burdick - Burlingame CA, US
Mark S. Stanley - Pacifica CA, US
David Oare - Belmont CA, US
Mark E. Reynolds - Millbrae CA, US
Thomas R. Gadek - Oakland CA, US
James C. Marsters - Oakland CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K031/4525
C07D405/12

US Classification:

514326, 546214, 546225, 548200, 548517, 548537, 514330, 514365, 514422, 514423

Abstract:

The invention relates to novel compounds having formula (I) wherein Cy, X, Y, L and Rare as defined herein. The compounds bind CD11/CD18 adhesion receptors such as Lymphocyte Function-associated Antigen-1 (LFA-1) and are therefore useful for treating disorders mediated by LFA-1 such as inflammation and autoimmune diseases.

US Patent:

6933314, Aug 23, 2005

Filed:

Sep 30, 2003

Appl. No.:

10/676706

Inventors:

Dean R. Artis - Kensington CA, US
David Y. Jackson - San Bruno CA, US
Thomas E. Rawson - Mountain View CA, US
Mark E. Reynolds - Millbrae CA, US
Daniel P. Sutherlin - South San Francisco CA, US
Mark S. Stanley - Pacifica CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K031/403
C07D209/82

US Classification:

514411, 548440, 548444

Abstract:

Provided are compounds of formula (I) wherein A, Q, W, X, Y, Z, Rto R, m and n are as defined herein. Compounds of the invention bind to αintegrin receptors and thereby inhibit binding of ligands for αintegrins which is useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with αintegrins or their ligands.

US Patent:

7094869, Aug 22, 2006

Filed:

Aug 19, 2002

Appl. No.:

10/224640

Inventors:

Todd C. Somers - Foster City CA, US
Kathleen A. Elias - San Francisco CA, US
Ross G. Clark - Pacifica CA, US
Robert S. McDowell - San Francisco CA, US
Mark S. Stanley - Pacifica CA, US
John P. Burnier - Pacifica CA, US
Thomas E. Rawson - Mountain View CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

C07K 5/08

US Classification:

530331, 530330, 517 17, 517 18

Abstract:

The present invention comprises growth hormone releasing peptides/peptidomimetics (GHRP) capable of causing release of growth hormone from the pituitary. Compositions containing the GHRP's of this invention are used to promote growth in mammals either alone or in combination with other growth promoting compounds, especially IGF-1. In a method of this invention GHRP's in combination with IGF-1 are used to treat Type II diabetes. An exemplary compound of this invention is provided below.

US Patent:

7265146, Sep 4, 2007

Filed:

Apr 20, 2005

Appl. No.:

11/111105

Inventors:

Dean R. Artis - Kensington CA, US
David Y. Jackson - San Bruno CA, US
Thomas E. Rawson - Mountain View CA, US
Mark E. Reynolds - Millbrae CA, US
Daniel P. Sutherlin - South San Francisco CA, US
Mark S. Stanley - Pacifica CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K 31/403
C07D 207/04
C07D 209/82

US Classification:

514411, 548427, 548439, 548440, 548444, 548530, 548537, 548538, 514408, 514423

Abstract:

Provided are compounds of formula (I).

US Patent:

7739762, Jun 22, 2010

Filed:

Oct 20, 2008

Appl. No.:

12/288516

Inventors:

Steve Lamb - Union City CA, US
Mark Stanley - Union City CA, US
Michael Demaria - Union City CA, US

Assignee:

Mizuho Orthopedic Systems, Inc. - Union City CA

International Classification:

A61G 13/08
A61G 13/02

US Classification:

5618, 5621

Abstract:

A surgery table utilizing first and second sections which are hingedly attached to one another. First and second sections are also connected to supports apart from the hinged portion. An elevator moves one of the sections upwardly and downwardly at the support. The resultant position of the frame formed by the first and second sections may take the configuration of a flat surface or an upwardly or downwardly oriented “vee”.

US Patent:

7855216, Dec 21, 2010

Filed:

Nov 29, 2007

Appl. No.:

11/947656

Inventors:

Simon Charles Goodacre - Harlow, GB
Karen Williams - Harlow, GB
Stephen Price - Harlow, GB
Hazel Joan Dyke - Harlow, GB
John Gary Montana - Harlow, GB
Mark S. Stanley - Pacifica CA, US
Liang Bao - Daly City CA, US
Wendy Lee - San Ramon CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

C07D 471/04
A61K 31/437
A61P 29/00
A61P 35/00
C07D 487/04
A61K 31/519
A61K 31/5025

US Classification:

514300, 514248, 5142651, 544235, 544253, 546113

Abstract:

The invention relates to azaindolyl compounds of Formula I with anti-cancer and/or anti-inflammatory activity and more specifically to azaindolyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.